TrustCore Financial Services’s Karyopharm Therapeutics KPTI Stock Holding History

TrustCore Financial Services’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-20	Closed	-$6K	–	885
2020 Q2	$6K	Hold	20	–	–	﹤0.01%	689
2020 Q1	$6K	Hold	20	–	–	﹤0.01%	667
2019 Q4	$6K	Hold	20	–	–	﹤0.01%	708
2019 Q3	$3K	Hold	20	–	–	﹤0.01%	825
2019 Q2	$2K	Hold	20	–	–	﹤0.01%	842
2019 Q1	$2K	Hold	20	–	–	﹤0.01%	768
2018 Q4	$3K	Hold	20	–	–	﹤0.01%	375
2018 Q3	$5K	Hold	20	–	–	﹤0.01%	666
2018 Q2	$5K	Hold	20	–	–	﹤0.01%	676
2018 Q1	$4K	Hold	20	–	–	﹤0.01%	602
2017 Q4	$3K	Buy	+20	New	+$3.21K	﹤0.01%	603

Other funds holding KPTI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

TrustCore Financial Services's KPTI Position: Q3 2020 in Review

TrustCore Financial Services sold out of Karyopharm Therapeutics (KPTI) in Q3 2020, closing a stake of 20 shares — an estimated $6K sold.

TrustCore Financial Services first reported a position in KPTI in Q4 2017 and held it in 11 quarters. The position peaked at $6K in Q2 2020. 157 funds tracked by Wall St. Rank hold KPTI as of Q3 2020.

TrustCore Financial Services reported no remaining Karyopharm Therapeutics position as of Q3 2020 after selling out during the quarter.
TrustCore Financial Services sold 20 Karyopharm Therapeutics shares in Q3 2020, an estimated $6K.
TrustCore Financial Services first reported a position in Karyopharm Therapeutics in Q4 2017 and held it in 11 quarters.
TrustCore Financial Services's Karyopharm Therapeutics position peaked at $6K in Q2 2020.
157 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2020.

Based on TrustCore Financial Services's 13F filing for Q3 2020, filed 2 Nov 2020.